Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Asia-Pacific Journal of Clinical Oncology|March 3, 2018
Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancersCrescens Tiu, Annie Wong, Alan Herschtal, et al.Critical Reviews in Oncology/Hematology|January 22, 2021
Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspectiveJulia Lai-Kwon, Crescens Tiu, Abhijit Pal, et al.Asia-Pacific Journal of Clinical Oncology|April 10, 2015
Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for managementCrescens Tiu, Carmel Pezaro, Ian D Davis, et al.Oncology|July 3, 2019
Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical TrialsCrescens Tiu, Zoe Loh, Chun Loo Gan, et al.Journal of Immunotherapy and Precision Oncology|June 6, 2022
A Wolf in Sheep's Clothing: Systemic Immune Activation Post ImmunotherapyCrescens Tiu, Rajiv Shinde, Abhijit Pal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical TrialsAngelika Terbuch, Crescens Tiu, Irene Moreno Candilejo, et al.Cancer Treatment and Research Communications|February 7, 2021
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit ExperienceAndrea Biondo, Abhijit Pal, Ruth Riisnaes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastomaCrescens Tiu, Wing Yau, Diogo Silva, et al.Nature Communications|March 6, 2026
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapyWinnie Fernando, Jarama Clucas, Alberto Rizzo, et al.Immunity|May 24, 2024
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell deathJonathan Mannion, Valentina Gifford, Benjamin Bellenie, et al.Pageof 2